CytoDyn has lost its chief scientific officer Mahboob Rahman, M.D., Ph.D., just six months into his tenure at the biotech and after a flopped COVID-19 trial.
Medable has had a strong 12 months, with the pandemic putting its siteless trial approach on the map and helping it make millions in funding; now, it’s hired a prestigious chief scientific officer in Pamela Tenaerts, M.D.
As a senior executive at Thermo Fisher Scientific, Yan Zhang wasn’t really on the hunt for a new job. But when a recruiter came along with a CEO role at an up-and-coming genomics company, Zhang found the offer hard to resist.
Ventus Therapeutics has raised a $100 million series B to take small molecules against traditionally undruggable targets into clinical trials. The pipeline features NLRP3 inhibitors that Ventus is pitching as best-in-class candidates in the competitive inflammasome space.
Alongside raising $220 million in new venture capital, digital healthcare mapmaker Komodo Health has charted a partnership with Johnson & Johnson’s pharmaceutical wing, Janssen Research & Development, to help provide real-world data and artificial intelligence-powered analysis.
Novartis has struck a deal with Artios Pharma to access DNA damage response (DDR) targets with the potential to enhance its radioligand therapies. Artios, which is run by some of the people behind pioneering DDR drug Lynparza, is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets.
Bristol Myers Squibb and PsiOxus Therapeutics are expanding their partnership—again. The duo first teamed up in June 2016 to study the latter’s cancer-killing virus, inking a deal later that year to combine the virus with BMS’ checkpoint inhibitor, Opdivo. Now, they’re adding a second asset from PsiOxus to the mix.
Metagenomi has added a cool $10 million extra to its series A funding round with help from RA Capital as it also adds the VC firm’s M.D. to the board.
Metastatic cancer is responsible for most cancer deaths, but people whose disease has spread to other parts of the body don’t have enough effective treatment options. Volastra Therapeutics wants to change that by developing drugs that target chromosomal instability, a hallmark of solid tumors that’s linked to metastasis.
It’s been a busy day for Invitae. The genetic testing provider inked a $200 million buyout and wrapped up a hefty investment from a group of backers marshaled by SoftBank.